Lumify Ad Launches As Bausch Spends More Behind OTC Eye Care Brands
Executive Summary
Following first anniversary of Lumify launch, "we're still in a pretty heavy investment period supporting trial because our data suggest that when people use the product, they persist in using the product. And so for now, we got our foot down on of the promotional side," says CFO Paul Herendeen.
You may also be interested in...
Lumify Reaches Canada As Consumer Health Leads Sales In Bausch + Lomb's Debut Quarter
Lumify sales grew reported 21% to brand-record $35m in Q2, Bausch + Lomb’s first quarter since separating from Bausch Health through an IPO in May.
Bausch's Lumify Eye Drops Sales Jump To Double Competitors' Market Share
Lumify redness relief eye drops nearly doubled in sales between Bausch's second and third quarters and drove 7% organic growth of its global consumer business compared to the year-ago period. The brand has double the market share of its two closest competitors, and the firm plans clinical studies for product extensions to the brand in 2020.
Bausch Sees Sales Drivers In Lumify, Ocuvite And PreserVision Line Extensions
Lumify reached 35% market share in US OTC eye drops and Ocuvite and Preservision vision health supplements are the No. 2 sales driver across Bausch's total portfolio.